Log in

NYSEAMERICAN:OCX - OncoCyte Stock Price, Forecast & News

$2.21
+0.16 (+7.80 %)
(As of 12/16/2019 06:00 AM ET)
Today's Range
$2.09
Now: $2.21
$2.25
50-Day Range N/A
52-Week Range
$1.16
Now: $2.21
$6.92
Volume404,492 shs
Average Volume530,086 shs
Market Capitalization$114.86 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
OncoCyte Corporation focuses on the development and commercialization of novel and non-invasive blood and urine (liquid biopsy) diagnostic tests for the early detection of cancer. The company is developing diagnostic tests using genetic and protein markers expressed in various types of cancer. It develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancer. Read More…

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:OCX
CUSIPN/A
Phone(510) 775-0515

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees12
Market Cap$114.86 million
Next Earnings Date4/6/2020 (Estimated)
OptionableNot Optionable

Receive OCX News and Ratings via Email

Sign-up to receive the latest news and ratings for OCX and its competitors with MarketBeat's FREE daily newsletter.


OncoCyte (NYSEAMERICAN:OCX) Frequently Asked Questions

What is OncoCyte's stock symbol?

OncoCyte trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "OCX."

How were OncoCyte's earnings last quarter?

OncoCyte Corp (NYSEAMERICAN:OCX) issued its quarterly earnings data on Wednesday, August, 14th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.10). View OncoCyte's Earnings History.

When is OncoCyte's next earnings date?

OncoCyte is scheduled to release their next quarterly earnings announcement on Monday, April 6th 2020. View Earnings Estimates for OncoCyte.

What price target have analysts set for OCX?

5 brokerages have issued twelve-month target prices for OncoCyte's shares. Their forecasts range from $6.00 to $7.75. On average, they expect OncoCyte's share price to reach $6.94 in the next year. This suggests a possible upside of 213.9% from the stock's current price. View Analyst Price Targets for OncoCyte.

What is the consensus analysts' recommendation for OncoCyte?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OncoCyte in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for OncoCyte.

Has OncoCyte been receiving favorable news coverage?

News articles about OCX stock have trended negative recently, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. OncoCyte earned a news sentiment score of -2.8 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for OncoCyte.

Who are some of OncoCyte's key competitors?

What other stocks do shareholders of OncoCyte own?

Who are OncoCyte's key executives?

OncoCyte's management team includes the folowing people:
  • Mr. William Annett, Pres, CEO & Director (Age 65)
  • Mr. Mitchell S. Levine, Chief Financial Officer
  • Dr. Lyndal K. Hesterberg, Chief Scientific Officer
  • Mr. Albert P. Parker II, Chief Operating Officer
  • Dr. Michael D. West, Scientific Advisor, Co-CEO of Biotime,Inc. & Pres of Biotime,Inc. (Age 66)

Who are OncoCyte's major shareholders?

OncoCyte's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Emerald Mutual Fund Advisers Trust (4.68%), State Street Corp (0.81%), Doheny Asset Management CA (0.27%) and Millennium Management LLC (0.10%). Company insiders that own OncoCyte stock include Andrew Arno, Biotime Inc, Broadwood Partners, LP, Mitchell S Levine and Thomas Alex Vetter. View Institutional Ownership Trends for OncoCyte.

Which institutional investors are buying OncoCyte stock?

OCX stock was purchased by a variety of institutional investors in the last quarter, including Doheny Asset Management CA, State Street Corp, Emerald Mutual Fund Advisers Trust and Millennium Management LLC. Company insiders that have bought OncoCyte stock in the last two years include Andrew Arno, Broadwood Partners, LP, Mitchell S Levine and Thomas Alex Vetter. View Insider Buying and Selling for OncoCyte.

How do I buy shares of OncoCyte?

Shares of OCX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is OncoCyte's stock price today?

One share of OCX stock can currently be purchased for approximately $2.21.

How big of a company is OncoCyte?

OncoCyte has a market capitalization of $114.86 million. OncoCyte employs 12 workers across the globe.View Additional Information About OncoCyte.

What is OncoCyte's official website?

The official website for OncoCyte is http://www.oncocyte.com/.

How can I contact OncoCyte?

OncoCyte's mailing address is 1010 Atlantic Ave Ste 102, ALAMEDA, CA 94501-1147, United States. The biotechnology company can be reached via phone at (510) 775-0515.


MarketBeat Community Rating for OncoCyte (NYSEAMERICAN OCX)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  151 (Vote Outperform)
Underperform Votes:  123 (Vote Underperform)
Total Votes:  274
MarketBeat's community ratings are surveys of what our community members think about OncoCyte and other stocks. Vote "Outperform" if you believe OCX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OCX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/16/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel